Dec 11, 2008
By:
Patrick Clinton
Two years ago, an internal Merck survey revealed that its basic research operation was "every flavor of what you don't want." Today the company is in the midst of implementing a new strategy that groups scientists at sites dedicated to particular clinical areas. VP Kathleen Metters explains why - and how.
|
Dec 1, 2008
By:
Patrick Clinton
Maybe what you're feeling isn't impending doom. Maybe it's just growing pains.
|
Somehow, the public has got it into its head that FDA should inspect all the world's drug plants. Aren't there better ways to ensure the safety of imported drugs?
Nov 1, 2008
By:
Patrick Clinton
Is FDA's MO in foreign inspections too broken to fix?
|
Nov 1, 2008
By:
Patrick Clinton
The former health secretary offers a reality check on healthcare reform—and what to expect from the pols in '09
|
Oct 1, 2008
By:
Patrick Clinton
A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
|
Sep 1, 2008
By:
Patrick Clinton
The United States makes the best medicines in the world. In days to come, that could be a problem.
|
Aug 1, 2008
By:
Patrick Clinton
There's a cure for everything, as long as the patient is a mouse
|
Aug 1, 2008
By:
Patrick Clinton
FDA preemption is a hot issue for pharma, and it's likely to get hotter. But it's the wrong issue.
|
It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with.
Jul 1, 2008
By:
Patrick Clinton
It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
